Purchase this article with an account.
Aihua Hou, Yohannes Abere Ambaw, Ming Yi Gan, Markus Wenk, Louis Tong; Involvement of eicosanoid in pterygium. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4706.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Pterygium is a benign outgrowth from conjunctiva to cornea, characterized by abnormal cell proliferation and increased inflammation. Eicosanoids are locally acting bioactive signaling lipids which regulate a diverse set of homeostatic and inflammatory processes, involved in numerous diseases. Previous study compared lipidomics of pterygium and donor cornea-scleral grafts, but this did not extend to small polar lipids like the eicosanoids.In this study, we compared eicosanoids between pterygium and conjunctiva tissues from the same patients.
Eleven pairs of pterygium and uninvolved conjunctiva tissues from the same eyes were harvested. Eicosanoids were extracted after homogenization through solid phase extraction (SPE) and analyzed using liquid chromatography mass spectrometry (LCMS). Sixty different eicosanoids were quantified using known internal standards and concentration normalized to 1 mg of total protein.
The levels of three eicosanoids were significantly dysregulated in pterygium prostaglandin (PGF2α), 15-hydroxyeicosatetraenoic acid (15-HETrE) and 15-oxo eicosatetraenoic (15-oxoETE). PGF2αlevel in pterygium was 1.3-fold higher as compared to conjunctiva; 15-HETrE and 15-oxo ETE levels were 2-fold higher as compared to control tissues. One eicosanoid, 5,6- EET, was 1.5-fold reduced in pterygium when compared to control.
Inflammation is the hallmark of pterygiumand specific eicosanoids may be involved in the process viaactions on immune cells or resolution of inflammation.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only